56
Participants
Start Date
December 14, 2018
Primary Completion Date
December 22, 2022
Study Completion Date
March 26, 2024
Nivolumab
"Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.~Patients in arm Metastatic CRPC will receive therapy with monotherapy nivolumab therapy at flat dose 480 mg IV every 4 weeks for up to 104 weeks of total therapy."
Ipilimumab
Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.
Memorial Sloan Kettering Cancer Center, New York
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
H. Lee. Moffitt Cancer Center & Research Institute, Inc., Tampa
University of Michigan Rogel Cancer Center, Ann Arbor
Karmanos Cancer Institute, Detroit
Siteman Cancer Center at Washington University, St Louis
University of California San Diego, Moores Cancer Center, San Diego
University of California San Francisco/Helen Diller Family Comprehensive Cancer Center, San Francisco
Memorial Sloan Kettering Cancer Center
OTHER
University of California, San Francisco
OTHER
University of Michigan Rogel Cancer Center
OTHER